Month: September 2021

CTP will help businesses committed to transition to a low-carbon economy in return for continued access to insurance capacity and capital LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Willis Towers Watson (NASDAQ: WLTW), a leading global advisory, broking, and solutions company, today announces that Liberty Specialty Markets has aligned capacity to support the Climate Transition Pathway (CTP) solution, an accreditation framework that provides insurance companies and financial institutions with a consistent approach to identifying businesses with robust low carbon transition plans aligned to the Paris Agreement. Liberty becomes the first major insurer to align capacity to support CTP which is a best practice industry accreditation model to help companies transition to a low carbon economy. Companies achieving accreditation will have...

Figure 12020 Drilling CampaignFigure 2Section Views of the Mineral Resource Classification of the Main OrebodyFigure 3Orthographic View of the Mineral Resource Estimation of the Main OrebodyFigure 4A Typical Section Through the Kobada OrebodyFigure 5Future Exploration Potential“We are delighted to announce these phenomenal results from our Kobada Gold Project in Mali. With the inclusion of significant exploration drilling within our oxides and fresh rock, we have achieved a substantial increase in total resource to more than 3.1 million ounces, which includes a 44% increase in Measured and Indicated resource of 1.71 million ounces, and a 26% increase in Inferred resource of 1.43 million ounces,” commented Danny Callow, CEO of African Gold Group Highlights:...

Municipality Finance PlcStock exchange release 2 September 2021 at 10:00 am (EEST) Municipality Finance issues EUR 20 million notes under MTN programme Municipality Finance Plc issues EUR 20 million notes on 3 September 2021. The maturity date for the notes is 3 September 2036. MuniFin has a right but no obligation to redeem the notes early on 3 September 2022 and every three years thereafter. For the first year, the notes bear interest at a fixed rate of 0.30% per annum. If MuniFin chooses not to redeem the notes early, the interest will increase by 0.05 percentage points after the first year and every three years thereafter on each possible early redemption date. The notes are issued under MuniFin’s EUR 40 billion programme for the issuance of debt instruments. The offering circular is available in English on the company’s website...

Montrouge, septembre 2nd, 2021CAPITAL INCREASE 2021RESERVED FOR EMPLOYEES OF THE CRÉDIT AGRICOLE GROUP Crédit Agricole SA today announces the launch of its annual share offering reserved for employees of the Crédit Agricole group, worldwide. Crédit Agricole S.A. will offer its 175,000 employees with at least three months of service in France and in 17 countries abroad, and its retired employees who have kept their assets in their PEE (Employee Savings Plan) in France, the opportunity to subscribe to new shares of Crédit Agricole S.A. under this reserved capital increase (ACR 2021). The subscription price of the share will be equal to the arithmetic average of the opening prices of the share between September 10 and October 7, 2021, with a discount of 20%. The subscription period will be open between October 8 and 22, 2021i. The new...

Marseille, France, Sept. 02, 2021 (GLOBE NEWSWIRE) — AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress. AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC).   Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed...

Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokinetics LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces an abstract describing a drug-drug interaction study assessing the effect of CYP2C9 inhibitor, fluconazole, on the pharmacokinetics of nebulized ensifentrine in healthy individuals has been published by the European Respiratory Society (“ERS”) International Congress 2021. The abstract is available on the ERS website and will appear in a supplement of the peer reviewed journal, European Respiratory Journal. Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and...

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial MARSEILLE, France, Sept. 02, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress. AstraZeneca will present a late-breaker abstract on the COAST Phase 2 trial, highlighting progression-free survival (PFS) results for novel durvalumab combinations with potential new medicines, including Innate’s monalizumab, and oleclumab, an anti-CD73 monoclonal antibody, in unresectable, Stage III non-small cell lung cancer (NSCLC).   Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed...

Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. and NEW YORK and LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a clinical stage biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody (mAb), as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy. The...